What's Happening?
Merck has announced a definitive agreement to acquire Terns Pharmaceuticals, a clinical-stage oncology company, for approximately $6.7 billion. This acquisition will expand Merck's hematology pipeline with Terns' lead candidate, TERN-701, an investigational
oral allosteric BCR::ABL1 tyrosine kinase inhibitor. TERN-701 is currently in Phase 1/2 development for patients with chronic myeloid leukemia (CML) who have experienced treatment failure or intolerance. The acquisition is expected to close in the second quarter of 2026, subject to customary conditions and regulatory approvals.
Why It's Important?
This acquisition is significant as it strengthens Merck's position in the oncology sector, particularly in hematology. TERN-701 has shown promising results in clinical trials, offering potential new treatment options for CML patients who have not responded well to existing therapies. The deal reflects Merck's commitment to diversifying its portfolio and advancing innovative cancer treatments. The acquisition also highlights the ongoing trend of large pharmaceutical companies investing in promising biotech firms to bolster their research and development pipelines.
What's Next?
The transaction is subject to approval by Terns' stockholders and regulatory authorities. Merck plans to integrate TERN-701 into its existing hematology research efforts, leveraging its resources to advance the development of this promising candidate. An investor call is scheduled to discuss the acquisition details, and further updates are expected as the transaction progresses towards completion.
